tbuckley/cabot-search huggingface dataset:
Diabetes care management during cancer treatment.
Authors: Gregory R. Harper, Janelle Sharma, Cara Habeck, Cathy Coyne, Hope Kincaid, Roya Hamadani, Ada Rivera, Gretchen Perilli, Nicole Sully
Journal: Journal of Clinical Oncology (2013)

189 Background: Cancer treatment negatively affects glucose control and puts patients at risk for hospital admissions. A one year medical record review at Lehigh Valley Hospital revealed that 75.4% of diabetic patients receiving treatment in the cancer center had at least one emergency department (ED) and/or inpatient (IP) admission—13.2% had a diabetes code present among the top 3 discharge diagnoses. We implemented a program in which a certified diabetes educator (CDE) and nurse practitioner worked with oncologists and primary care providers (PCP) to coordinate care for these patients. Methods: Cancer patients with diabetes or treatment related hyperglycemia were referred to the Diabetes Oncology Program for care management (CM). CM included patient assessment, education, care plan development, collaboration with PCP, and follow-up during treatment. A clinical practice guideline was developed for infusion nurses to treat hyperglycemia. Diabetes medications were modified during cancer treatment in collaboration with the PCP. CM ended at the conclusion of the course of treatment or with end of life care. Program evaluation consisted of patient and provider surveys, and analysis of ED/IP admissions. Results: In a preliminary analysis of 98 patients that received CM, 74 ED/IP admissions occurred between the first appointment with the CDE and the end of CM; 11 admissions (14.8%) were for diabetes or hyperglycemia related diagnosis. At baseline, participant mean FACT-G scores were slightly lower than published normative data for cancer patients. Significant improvements from baseline to 2 months post program enrollment were found among participants in diabetes empowerment and satisfaction with diabetes treatment scores. Provider survey responses at baseline found that PCPs are more satisfied with oncologist communication than oncologists are with PCP communication. Final results of the patient and provider surveys and program impact on ED/IP admissions will be presented. Conclusions: Patient empowerment and satisfaction with treatment may be improved by focused diabetes care management. Final data analyses will indicate if this improvement is achieved along with reductions in ED/IP admissions for diabetes related diagnoses among cancer patients.
Cyclophosphamide and targeted dose topotecan with autologous hematopoietic stem cell rescue for solid tumors
Authors: G. Hale, L. Bowman, C. Stewart, E. Horwitz, W. Leung, E. Benaim, P. Woodard, X. Tong, D. K. Srivastava, R. Handgretinger
Journal: Journal of Clinical Oncology (2004)

8534 Background: Autologous HSCT is curative for some children with high-risk solid tumors and lymphomas; however, no conditioning regimen has proven superior. In this phase II trial, we studied the antitumor response of the novel combination of cyclophosphamide and targeted-dose topotecan with stem cell support. Methods: Patients less than 25 years of age with a chemosensitive solid tumor or lymphoma at high risk of relapse or progression were eligible. Topotecan was administered intravenously once daily for 10 days at an initial dose of 3 mg/m2 with subsequent doses adjusted to achieve an AUC of 100 ± 20 ng-hr/ml. During the last 5 days, cyclophosphamide with mesna uroprotection was administered following the topotecan. At level 1, the cyclophosphamide dose was 750 mg/m2/day; at level 2 the dose was 1000 mg/m2/day. Results: Between November 1998 and October 2002, 56 patients with a median age of 5.7 years (1.2–21.3) were enrolled. Diagnoses included neuroblastoma (46.4%), sarcoma (21.4%), lymphoma (16.1%), brain tumor (8.9%), Wilms' tumor (5.4%), and retinoblastoma (1.8%). 24 were in remission at HSCT (43%); 32 had persistent disease (57%). 35 patients received a bone marrow graft; 21 received peripheral blood stem cells. The median time to neutrophil engraftment was 14 days; the median time to platelet engraftment was 23 days. 43 patients (77%) remain alive. 13 have died: 11 of disease recurrence and 2 of regimen-related toxicities. With a median follow-up of 20.1 months (0.7–59.4), 2 year overall survival was 93% for neuroblastoma, 78% for lymphomas 68% for sarcomas, and 22% for other tumors. 2 year disease-free survival (DFS) was 41% for neuroblastoma, 67% for lymphoma, 51% for sarcomas, and 33% for other tumors. The 2 year overall DFS was 50% for the entire cohort. The median time to recurrence was 5.8 months (1.2–15.2). Patients with residual disease at transplant had similar DFS as those in remission (51% vs. 49%). Conclusions: The combination of cyclophosphamide and targeted topotecan with autologous HSCT yields favorable outcomes for children with high-risk solid tumors and lymphomas, particularly sarcomas. Additional investigation is warranted. No significant financial relationships to disclose.
Chitosan‐Gated Magnetic‐Responsive Nanocarrier for Dual‐Modal Optical Imaging, Switchable Drug Release, and Synergistic Therapy
Authors: Hui Wang, Qingxin Mu, Richard Revia, Kui Wang, Xuezhe Zhou, Peter J. Pauzauskie, Shuiqin Zhou, Miqin Zhang
Journal: Advanced Healthcare Materials (2017)

A dual-layer shell hollow nanostructure as drug carrier that provides instant on/off function for drug release and contrast enhancement for multimodal imaging is reported. The on-demand drug release is triggered by irradiation of an external magnetic field. The nanocarrier also demonstrates a high drug loading capacity and synergistic magnetic-thermal and chemotherapy.
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial
Authors: J. Liang, N. Bi, S. Wu, M. Chen, C. Lv, L. Zhao, A. Shi, W. Jiang, Y. Xu, Z. Zhou, W. Wang, D. Chen, Z. Hui, J. Lv, H. Zhang, Q. Feng, Z. Xiao, X. Wang, L. Liu, T. Zhang, L. Du, W. Chen, Y. Shyr, W. Yin, J. Li, J. He, L. Wang
Journal: Annals of Oncology (2017)
Senior doctors urge prime minister to act on underfunded NHS
Authors: Zosia Kmietowicz
Journal: BMJ (2017)

More than 2000 senior NHS doctors have signed a letter calling on the prime minister, Theresa May, to increase spending on health and social care because “unacceptable levels of safety concerns” mean that things “simply cannot continue” the way they are.1

The doctors who organised the letter—Anita Sugavanam, a consultant anaesthetist, and Rob Galloway, an emergency medicine consultant at Brighton and Sussex University Hospital—said that the letter was …
Role of High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Men With Previously Treated Germ Cell Tumors
Authors: Lance C. Pagliaro
Journal: Journal of Clinical Oncology (2017)

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 39-year-old, previously healthy man presented with a left testicular mass, confirmed on ultrasound. He underwent left inguinal orchiectomy, which disclosed testicular carcinoma composed of 90% choriocarcinoma, 9% seminoma, and 1% teratoma. Imaging revealed numerous metastases in the lungs, liver, and brain. Prechemotherapy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, human chorionic gonadotropin (hCG) 151,111 IU/L, and lactate dehydrogenase 588 U/L. He received four courses of etoposide, ifosfamide, and cisplatin chemotherapy, given without bleomycin because of the anticipated need for postchemotherapy thoracic surgery. He had an incomplete response to induction chemotherapy. The serum hCG level was 8.1 IU/L, and there were residual lesions in the liver and lungs whereas the brain metastases had nearly resolved. His Eastern Cooperative Oncology Group performance status was zero. He had no symptoms of ototoxicity or peripheral neurotoxicity. Repeat serum hCG levels after chemotherapy were 12.3 IU/L at 2 weeks and 325 IU/L at 4 weeks. He was referred to discuss optimal ongoing treatment.
Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma
Authors: Lindsey N. Kent, Sooin Bae, Shih-Yin Tsai, Xing Tang, Arunima Srivastava, Christopher Koivisto, Chelsea K. Martin, Elisa Ridolfi, Grace C. Miller, Sarah M. Zorko, Emilia Plevris, Yannis Hadjiyannis, Miguel Perez, Eric Nolan, Raleigh Kladney, Bart Westendorp, Alain de Bruin, Soledad Fernandez, Thomas J. Rosol, Kamal S. Pohar, James M. Pipas, Gustavo Leone
Journal: Journal of Clinical Investigation (2017)

Disruption of the retinoblastoma (RB) tumor suppressor pathway, either through genetic mutation of upstream regulatory components or mutation of RB1 itself, is believed to be a required event in cancer. However, genetic alterations in the RB-regulated E2F family of transcription factors are infrequent, casting doubt on a direct role for E2Fs in driving cancer. In this work, a mutation analysis of human cancer revealed subtle but impactful copy number gains in E2F1 and E2F3 in hepatocellular carcinoma (HCC). Using a series of loss- and gain-of-function alleles to dial E2F transcriptional output, we have shown that copy number gains in E2f1 or E2f3b resulted in dosage-dependent spontaneous HCC in mice without the involvement of additional organs. Conversely, germ-line loss of E2f1 or E2f3b, but not E2f3a, protected mice against HCC. Combinatorial mapping of chromatin occupancy and transcriptome profiling identified an E2F1- and E2F3B-driven transcriptional program that was associated with development and progression of HCC. These findings demonstrate a direct and cell-autonomous role for E2F activators in human cancer.
Prevention of Hemophagocytosis by TNF-α and IL-6 Blockade in TLR9- and Nod1- Ligand Induced Hemophagocytic Syndrome.
Authors: Hideaki Ohyagi, Nobuyuki Onai, Yong-Mei Guo, Naoto Takahashi, Makoto Hirokawa, Ken-Ichi Sawada, Toshiaki Ohteki
Journal: Blood (2009)
Prognostic Value of Early Treatment Response in Children with Acute Lymphoblastic Leukemia: A Single Institution Experience in Shanghai, China.
Authors: Li-Jun Tie, Long-Jun Gu, De-Lian Song, Li-Ming Jiang, Hui-Liang Xue, JingYan Tang, Lu Dong, Ci Pan, Jing Chen, Yao-Ping Wang, Jing Chen
Journal: Blood (2004)
Effects of Delayed Umbilical Cord Clamping vs Early Clamping on Anemia in Infants at 8 and 12 Months
Authors: Ashish KC, Nisha Rana, Mats Målqvist, Linda Jarawka Ranneberg, Kalpana Subedi, Ola Andersson
Journal: JAMA Pediatrics (2017)

Delayed umbilical cord clamping has been shown to improve iron stores in infants to 6 months of age. However, delayed cord clamping has not been shown to prevent iron deficiency or anemia after 6 months of age.To investigate the effects of delayed umbilical cord clamping, compared with early clamping, on hemoglobin and ferritin levels at 8 and 12 months of age in infants at high risk for iron deficiency anemia.This randomized clinical trial included 540 late preterm and term infants born vaginally at a tertiary hospital in Kathmandu, Nepal, from October 2 to November 21, 2014. Follow-up included blood levels of hemoglobin and ferritin at 8 and 12 months of age. Follow-up was completed on December 11, 2015. Analysis was based on intention to treat.Infants were randomized to delayed umbilical cord clamping (≥180 seconds after delivery) or early clamping (≤60 seconds after delivery).Main outcomes included hemoglobin and anemia levels at 8 months of age with the power estimate based on the prevalence of anemia. Secondary outcomes included hemoglobin and anemia levels at 12 months of age and ferritin level, iron deficiency, and iron deficiency anemia at 8 and 12 months of age.In this study of 540 infants (281 boys [52.0%] and 259 girls [48.0%]; mean [SD] gestational age, 39.2 [1.1] weeks), 270 each were randomized to the delayed and early clamping groups. At 8 months of age, 212 infants (78.5%) from the delayed group and 188 (69.6%) from the early clamping group returned for blood sampling. After multiple imputation analysis, infants undergoing delayed clamping had higher levels of hemoglobin (10.4 vs 10.2 g/dL; difference, 0.2 g/dL; 95% CI, 0.1 to 0.4 g/dL). Delayed cord clamping also reduced the prevalence of anemia (hemoglobin level <11.0 g/dL) at 8 months in 197 (73.0%) vs 222 (82.2%) infants (relative risk, 0.89; 95% CI, 0.81-0.98; number needed to treat [NNT], 11; 95% CI, 6-54). At 8 months, the risk for iron deficiency was reduced in the delayed clamping group in 60 (22.2%) vs 103 (38.1%) patients (relative risk, 0.58; 95% CI, 0.44-0.77; NNT, 6; 95% CI, 4-13). At 12 months, delayed cord clamping still resulted in a hemoglobin level of 0.3 (95% CI, 0.04-0.5) g/dL higher than in the early cord clamping group and a relative risk for anemia of 0.91 (95% CI, 0.84-0.98), resulting in a NNT of 12 (95% CI, 7-78).Delayed cord clamping reduces anemia at 8 and 12 months of age in a high-risk population, which may have major positive effects on infants' health and development.clinicaltrials.gov Identifier: NCT02222805.
CD24-Siglec-G Interaction Plays an Important in Reducing Experimental Graft-Versus-Host Disease (GVHD)
Authors: Tomomi Toubai, Rebecca Evers, Yaping Sun, Isao Tawara, Chen Liu, Hiroya Tamaki, Nathan Mathewson, Evelyn Nieves, Michael Bassetti, Pan Zheng, Yang Liu, Pavan Reddy
Journal: Blood (2012)
Trusts introduce bedside eyesight check to reduce inpatient falls
Authors: Susan Mayor
Journal: BMJ (2017)

A tool to help hospital ward staff quickly assess a patient’s eyesight has been introduced for use by trusts in England and Wales with the aim of reducing trips and falls while patients are in hospital.

The tool uses a mixture of questions and visual aids to help doctors, nurses, or therapists check a patient’s eyesight at the hospital bedside.1 Results give an indication of the extent of any …
Imatinib Increases Cytotoxicity of Melphalan and Their Combination Allows An Efficient Killing of CML Cells.
Authors: Cesarina Giallongo, Piera La Cava, Daniele Tibullo, Nunziatina Parrinello, Provvidenza Guagliardo, Vittorio Del Fabro, Fabio Stagno, Annalisa Chiarenza, Carla Consoli, Paolo Spina, Paolo Vigneri, Giuseppe A Palumbo, Francesco Di Raimondo
Journal: Blood (2009)
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis
Authors: Carol A. Langford, David Cuthbertson, Steven R. Ytterberg, Nader Khalidi, Paul A. Monach, Simon Carette, Philip Seo, Larry W. Moreland, Michael Weisman, Curry L. Koening, Antoine G. Sreih, Robert Spiera, Carol A. McAlear, Kenneth J. Warrington, Christian Pagnoux, Kathleen McKinnon, Lindsy J. Forbess, Gary S. Hoffman, Renée Borchin, Jeffrey P. Krischer, Peter A. Merkel
Journal: Arthritis & Rheumatology (2017)

Objective To compare the efficacy of abatacept to that of placebo for the treatment of giant cell arteritis (GCA). Methods In this multicenter trial, patients with newly diagnosed or relapsing GCA were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with prednisone administered daily. At week 12, patients in remission underwent a double‐blinded randomization to continue to receive abatacept monthly or switch to placebo. Patients in both study arms received a standardized prednisone taper, with discontinuation of prednisone at week 28. All patients remained on their randomized assignment until meeting criteria for early termination or until 12 months after enrollment of the last patient. The primary end point was duration of remission (relapse‐free survival rate). Results Forty‐nine eligible patients with GCA were enrolled and treated with prednisone and abatacept; of these, 41 reached the week 12 randomization and underwent a blinded randomization to receive abatacept or placebo. Prednisone was tapered using a standardized schedule, reaching a daily dosage of 20 mg at week 12 with discontinuation in all patients at week 28. The relapse‐free survival rate at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo ( P = 0.049). A longer median duration of remission was seen in those receiving abatacept compared to those receiving placebo (median duration 9.9 months versus 3.9 months; P = 0.023). There was no difference in the frequency or severity of adverse events, including infection, between the treatment arms. Conclusion In patients with GCA, the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone.
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
Authors: Viktoras Frismantas, Maria Pamela Dobay, Anna Rinaldi, Joelle Tchinda, Samuel H. Dunn, Joachim Kunz, Paulina Richter-Pechanska, Blerim Marovca, Orrin Pail, Silvia Jenni, Ernesto Diaz-Flores, Bill H. Chang, Timothy J. Brown, Robert H. Collins, Sebastian Uhrig, Gnana P. Balasubramanian, Obul R. Bandapalli, Salome Higi, Sabrina Eugster, Pamela Voegeli, Mauro Delorenzi, Gunnar Cario, Mignon L. Loh, Martin Schrappe, Martin Stanulla, Andreas E. Kulozik, Martina U. Muckenthaler, Vaskar Saha, Julie A. Irving, Roland Meisel, Thomas Radimerski, Arend Von Stackelberg, Cornelia Eckert, Jeffrey W. Tyner, Peter Horvath, Beat C. Bornhauser, Jean-Pierre Bourquin
Journal: Blood (2017)
Improving Access to Evidence-Based Antipoverty Government Programs in the United States
Authors: Michael K. Hole, Lucy E. Marcil, Robert J. Vinci
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma
Authors: Z.J. Wolner, A.A. Marghoob, M.P. Pulitzer, M.A. Postow, M.A. Marchetti
Journal: British Journal of Dermatology (2017)

Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death (PD)‐1 receptor. Common cutaneous adverse side‐effects of PD‐1 inhibitors include maculopapular rash, pruritus, vitiligo and lichenoid skin and mucosal reactions. Here we describe a man in his sixties with metastatic melanoma treated with pembrolizumab who subsequently developed fading or disappearance of pigmented skin lesions, lightening of the skin, and poliosis of the eyebrows, eyelashes and scalp and body hair. Compared with baseline high‐resolution three‐dimensional total‐body photography, we observed fading or disappearance of solar lentigines, seborrhoeic keratoses and melanocytic naevi, suggesting that PD‐1 inhibitors may affect the evolution of these benign skin lesions. With dermatoscopic follow‐up, altered lesions showed either blue‐grey peppering/granularity or fading in colour without other identifiable features. No halo lesions or lesions with surrounding inflammation were identified. One changed pigmented lesion that showed blue‐grey peppering/granularity on dermoscopy was biopsied and interpreted as a macular seborrhoeic keratosis with melanophages. Further studies are required to elucidate the effects of PD‐1 inhibition on benign skin lesions.
An Fc-Optimized Monoclonal Antibody Against CD32B, the Human Inhibitory Fc-γ Receptor IIB, in the Immunotherapy of B-Cell Malignanacy.
Authors: Jeffrey B. Stavenhagen, Sergey Gorlatov, Nadine Tuaillon, Christopher T. Rankin, Maria-Concetta Veri, David Inzunza, Stephen Burke, Ling Huang, Hua Li, Shannon Thomas, Syd Johnson, Jeffrey Ravetch, Scott Koenig, Ezio Bonvini
Journal: Blood (2006)
The JAK2 46/1 Haplotype Analysis In Essential Thrombocythaemia and Polycythaemia Rubra Vera Reveals That CC Genotype Is Associated with a Higher JAK2V617F and c-MPL W515 Allele Burden
Authors: Shameem Mahmood, Louise Mellish, Nicholas Lea, Austin G Kulasekararaj, Atiyeh Abdallah, Sivatharsny Srirangan, Ghulam J. Mufti
Journal: Blood (2010)
Development of a Right Ventricular Outflow Tract Gradient During Upright Exercise
Authors: Annelieke C.M.J. van Riel, David M. Systrom, Rudolf K.F. Oliveira, Michael J. Landzberg, Barbara J.M. Mulder, Berto J. Bouma, Bradley A. Maron, Amil M. Shah, Aaron B. Waxman, Alexander R. Opotowsky
Journal: Journal of the American College of Cardiology (2017)
Abstract 15054: IP3 Receptor Modulates Maladaptive Vascular Responses in Heart Failure
Authors: Gaetano Santulli, Steven R Reiken, Qi Yuan, Andrew Marks
Journal: Circulation (2016)

Introduction: Patients with heart failure (HF) have augmented vascular tone which increases cardiac workload, impairing cardiac output and adversely affecting outcomes. However, the molecular mecha...
Regulatory T Cells Enhance the Allogeneic Activity of Endothelial-Specific Cytotoxic T Lymphocytes – Protective Effect of Defibrotide
Authors: Guenther Eissner, Isabel Hartmann, Altug Kesikli, Silvia Haffner, Tanja Sax, Ernst Holler, Massimo Iacobelli
Journal: Blood (2011)
Antifungal Prophylaxis (AFP) for Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Undergoing Intensive Chemotherapy: An Experience with 730 Pts.
Authors: Gloria Mattiuzzi, Hagop Kantarjian, Jennifer Ho, Guillermo Garcia-Manero, Jorge Cortes
Journal: Blood (2009)
Selected Writings of Sir Charles Sherrington.
Journal: Annals of Internal Medicine (1941)

Selected Writings of Sir Charles Sherrington, Ziele, Adressen,     Mitglied in, Aktionen, Kontakt, Studio fur F.M. Alexander - Technik in Frankfurt am Main,     Lernen, Lehren, Voraussetzungen, Lektionen, Seminare, Veranstaltungen, Unterricht, Preise, Erfolge,     F.M. Alexander, Definition, Kommentare, Grundbegriffe, Literatur, Prominete, Aktion, Glossar,     Themen, Gesundheit am Arbeitsplatz, Augen, Kooperationen, Golf, Musik, Medizin, Yoga, Wellness,     Presse, Fachliteratur, Tageszeitungen, Periodika, Internet, Manuskripte,     Fragen, Wer macht, Wem hilft, Wer braucht, Was ist, Warum, Wozu, Welche Krankheiten, Zahlt Krankenkassen, Wie erklart